# Bausch Health Announces 2020 Annual Meeting Of Shareholder Results

April 29, 2020

LAVAL, Quebec, April 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the election of the eleven directors nominated at its 2020 annual meeting of shareholders held on April 28, 2020. The detailed results of the vote for the election of directors are set out below:

Name	For	Withheld	Broker Non-Votes
Richard U. De Schutter	216,315,704	5,259,134	59,178,282
D. Robert Hale	211,714,041	9,860,797	59,178,282
Dr. Argeris (Jerry) N. Karabelas	215,596,446	5,978,392	59,178,282
Sarah B. Kavanagh	217,011,297	4,563,541	59,178,282
Joseph C. Papa	212,494,697	9,080,141	59,178,282
John A. Paulson	219,853,068	1,721,770	59,178,282
Robert N. Power	208,740,697	12,834,141	59,178,282
Russel C. Robertson	215,372,886	6,201,952	59,178,282
Thomas W. Ross, Sr.	215,468,972	6,105,866	59,178,282
Andrew C. von Eschenbach, M.D.	219,493,913	2,080,925	59,178,282
Amy B. Wechsler, M.D.	216,271,318	5,303,520	59,178,282

At the annual meeting of shareholders, shareholders also approved in a non-binding advisory vote the compensation of the Company's named executive officers, an amendment to the Company's Amended and Restated 2014 Omnibus Incentive Plan to increase the number of common shares, no par value, of the Company authorized under such plan, and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2021 annual meeting of shareholders.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's website at

.

#### **About Bausch Health**

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at

www.bauschhealth.com

•	

Investor Contact:	Media Contact:
Arthur Shannon	Lainie Keller
arthur.shannon@bauschhealth.com	lainie.keller@bauschhealth.com
(514) 856-3855	(908) 927-1198

### **BAUSCH** Health

U

View original content to download multimedia:

http://www.prnewswire.com/news-releases/bausch-health-announces-2020-annual-meeting-of-s hareholder-results-301049711.html

SOURCE Bausch Health Companies Inc.

### **Investor Inquiries**





<u>ir@bauschhealth.com</u> 877-281-6642 514-856-3855 (Canada)

LEGAL NOTICE

**PRIVACY POLICY** 

EMAIL ALERTS

EMAIL PAGE

**RSS FEED** 

Media inquiries

<u>Corporate.communications@bauschhealth.com</u>

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

## CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u> <u>PERSONAL INFORMATION</u>

